ECMONet Webinar Series: Finding the right DOSE
Join A/Prof Ary Serpa Neto to learn more about the Daily Ordinal Scale for ECMO Patients (DOSE), a novel clinical outcome measure being used to select the right primary outcome for ECMO trials.
This free webinar will explore the rationale behind DOSE, its development incorporating consumer feedback, and the robust validation process using Bayesian Markov modelling. A/Prof Serpa Neto will discuss how DOSE may transform trial design by influencing interpretation, power calculations, and sample size requirements in ECMO research.
Presented by the International ECMO Network in partnership with the Critical Care Research Group and Monash University.
Date and Times:
San Francisco - 2.00pm Tuesday 24 March
New York - 5.00pm Tuesday 24 March
London - 9.00pm Tuesday 24 March
Rome - 10.00pm Tuesday 24 March
Melbourne - 8.00am Wednesday 25 March
Location: Webinar via Zoom
Register here - Zoom details will be emailed to you:
Meet your host, A/Prof Ary Serpa Neto
Ary Serpa Neto, MD, MSc, PhD is an Intensivist and Director of Intensive Care Research at Austin Hospital in Melbourne, Australia. He is also an Associate Professor at the Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), Monash University, where he leads the Mechanical Ventilation and Renal & Metabolic Programs. He is a founding member of the Protective Ventilation Network (PROVENet) and a member of the Scientific Committee of the Brazilian Research in Intensive Care Network (BRICNet). His research focuses on mechanical ventilation, renal and metabolic care, and advanced clinical trial methodology, with a strong emphasis on translating evidence into clinical practice.
Ary has authored over 480 publications, including multiple articles in The New England Journal of Medicine, JAMA, and The Lancet Respiratory Medicine, and his work has been cited in several international guidelines. He currently leads several large-scale international randomised clinical trials in Australia, including the NHMRC-funded SODa-BIC, DRIVE and GuARDS trials.